Members-only Site   |   Print Page   |   Contact Us   |   Sign In   |   Register
Capitol Connections April 4, 2014
Share |

April 4, 2014

House Health Subcommittee of the Energy and Commerce Committee to Hold Hearing on HR 4069

The House Health Subcommittee of the Energy & Commerce Committee will hold a hearing on HR 4069 introduced by Congressman Thomas Marino (R-PA). The hearing is scheduled for Monday, April 7, 2014, at 3:00 p.m. in Room 2123 of the Rayburn House Office Building. The hearing is entitled “Improving Predictability and Transparency in DEA and FDA Regulation.” The Drug Enforcement Administration (DEA) is expected to testify.

Subcommittee members will review three bills: H.R. 4299, the Improving Regulatory Transparency for New Medical Therapies Act, H.R. 4069, the Ensuring Patient Access and Effective Drug Enforcement Act, and H.R. 4250, the Sunscreen Innovation Act.

H.R. 4299, introduced by Pitts and Health Subcommittee Ranking Member Frank Pallone (D-NJ), would amend the Controlled Substances Act (CSA) to improve efficiency, transparency, and consistency of the Drug Enforcement Agency’s process for scheduling new drugs approved by the Food and Drug Administration. It would require DEA to make a final determination 45 days after receiving FDA’s scheduling recommendation for a new drug. Additionally, it would generate more transparency in the application process for clinical trials by requiring that DEA make a final determination within 180 days or provide the applicant with details about what outstanding issues remain unresolved.

H.R. 4069, introduced by full committee Vice Chairman Marsha Blackburn (R-TN) and Rep. Tom Marino (R-PA), would improve enforcement efforts regarding prescription drug diversion and abuse. The legislation would help prevent prescription drug abuse and diversion and ensure patient access to necessary medications by creating a more collaborative partnership between drug manufacturers, wholesalers, retail pharmacies and federal enforcement and oversight agencies.   

H.R. 4205, introduced by Rep. Ed Whitfield (R-KY) and Rep. John Dingell (D-MI), would expedite the FDA’s approval process for new sunscreen ingredients while maintaining strict safety standards. The FDA has not approved a new sunscreen ingredient in nearly two decades. This legislation would streamline the approval process and provide transparency with regular reports to Congress regarding progress and implementation. This legislation would require that applications currently pending approval be completed within eight months and that new applications be reviewed within 11 months. Senators Johnny Isakson (R-GA) and Jack Reed (D-RI) have introduced the Senate companion, S. 2141, to this bill.

IACP is monitoring this activity, and will send updates as they become available.

IACP Summary Available: President Obama Releases his Budget Requesting $4.7 Billion for FDA

The President released his budget on March 4th, requesting $4.7 billion for the Food and Drug Administration (FDA), which is $358 million, or 8% above the FY 2014 Enacted level. The President specifically requested $25 million of the total for agency-wide oversight of drug compounding, including enforcement, inspections, and collaboration with States. Click here to read IACP's comprehensive Summary of the FDA FY 2015 Budget. 

U.S. House Releases FY2015 Budget Plan

The U.S. House of Representatives this week released its FY2015 budget plan. IACP currently is reviewing the plan for any compounding requests. Click here for more information from the House. 

Bloomberg BNA Interviews IACP's David Miller

IACP's David G. Miller, Executive Vice President/CEO, is featured in an in-depth March 20, 2014, Bloomberg BNA article, "States Adopt Variety of Oversight Strategies in Wake of NECC Disaster." Miller explains the current environment of states updating their regulations over the past year since the NECC tragedy. Click here to read the article. It's a long, detailed article; but, worth the time to read! 

CVS & Federal Government Relationship Extends to 2017

According to a March 26th PR Newswire announcement - CVS Caremark Corporation announced that it has been awarded a three-year contract to provide integrated pharmacy benefit services for the Blue Cross and Blue Shield Government-wide Service Benefit Plan, also known as the Federal Employee Program (FEP). The Company will continue to provide retail pharmacy benefit management services, mail service pharmacy, specialty pharmacy services and highly customized clinical programs to FEP's more than 5 million federal employees, retirees and dependents. The new agreement, which runs through 2017, brings the relationship between CVS Caremark and FEP to more than 20 years.  

What to Consider if Compounding for Prison Executions

There are several business issues to consider when approached to compound a medication used for executions that are separate from the ethical and legal ones.

First, make sure your professional liability insurance provides coverage for such an action. Second, consider the potential security implications to your practice, your employees and your families. Given that the death penalty is a controversial and very high-profile issue, having your pharmacy known as the source of the lethal medicine may bring unwanted attention -- from the media, picketing by death penalty opponents, threats, etc.   

IACP Members: Please be aware that the media continues to explore the use of compounded drugs for prison executions. IACP has participated in several media interviews on this topic, including for a recent NPR story. Please click here to read. Please read our standard media statement below on this topic.

IACP Formal Statement Regarding Death Penalty

IACP has taken no formal position on compounding pharmacies’ preparation of drugs used in executions. The pharmacy profession recognizes an individual practitioner's right to refuse to dispense a medication based upon his or her personal, ethical and religious beliefs. In a very small number of cases, compounding pharmacies have been asked by their state government to assist in preparing drugs used in executions because pharmaceutical manufacturers have unilaterally restricted distribution. IACP believes Departments of Corrections should work first with the pharmacy services providers -- the companies that provide medications to prisoners within their systems -- to source or compound drugs for executions before soliciting a traditional compounding pharmacy.

Please email IACP should you have any questions at If you receive calls from the media, IACP encourages you to direct these press inquiries directly to your Academy's PR Firm, David Ball, Ball Consulting Group

David Ball, Ball Consulting Group, LLC
Office: 617-243-9950
Mobile: 617-548-7809

In Case You Missed It: FDA Responds to IACP Outsourcing Letter

IACP has been closely monitoring the U.S. Food & Drug Administration's (FDA) communications and activities regarding the newly established Outsourcing Facilities (OF). We are concerned regarding several areas on which we believe FDA has failed to provide guidance, causing considerable confusion for pharmacies. For example, the FDA sent letters to the States and to hospitals requesting that the hospitals only do business with registered OFs. FDA also asked States to implement a requirement that anyone who ships into their state to be registered as an OF. However, FDA hasn’t inspected any of these recently registered OFs; they have delayed the reporting requirements to OFs that register; and, FDA hasn’t developed any of the lists that dictate what OFs can compound. In addition, FDA hasn’t clarified with any pharmacies wishing to register as OFs whether they have to comply with the cGMPs, or whether FDA is drafting an alternative standard that will be enforced at these OFs. Thus, OFs are being asked to register, and they don’t even know to which standard of compliance they will be held.
With so much uncertainty, IACP sent a letter to the FDA asking that they cease sending letters endorsing these facilities when they haven’t developed any of the guidelines they were authorized to develop under HR 3204. This week, IACP received FDA’s response.
Click here to read IACP's letter to FDA. Click here  to read FDA's subsequent response.   

All pharmacies and pharmacists are licensed and strictly regulated by State Boards of Pharmacy. Compounding is a core component of pharmacy and has always been subject to the oversight and monitoring of these agencies and the state legislatures who decide upon the way pharmacy compounding should be regulated within their borders. Additionally, the Food & Drug Administration has authority over some aspects of compounded prescriptions at the federal level under the direction of Congress. Standards set by the United States Pharmacopeia (USP) are integrated into the day-to-day practice of pharmacy compounding and are mandated by law in most states. Even greater oversight comes through accreditation from a variety of non-profit agencies that establish and survey on guidelines designed to improve quality in the compounding process. 

Click here for FDA’s letter to hospitals promoting OFs

Click here for FDA's letter to States promoting OFs

Click here for IACP’s letter to FDA regarding promotion of OFs to States and hospitals

Click here for the FDA’s response to IACP

See Inside Health Policy article below.

Jurisdictional Issues Surface As States Mull Outsourcing-Facility Licensing
Posted: March 20, 2014

States are confused about how to apply licensing requirements to FDA's newly created category of outsourcing facilities, an International Academy of Compounding Pharmacists official said, citing an area that needs clarification as FDA implements the Drug Quality and Safety Act (DQSA). Sen. Lamar Alexander (R-TN), ranking member of the Senate health committee, recently touched on the issue in a hearing, saying states are considering laws that would also regulate outsourcing facilities.
David Miller, executive vice president and CEO of the International Academy of Compounding Pharmacists (IACP), said compounding pharmacies, like drug manufacturers, are involved with distributors, making states unsure about whether outsourcing facilities can be regulated under the Prescription Drug Marketing Act. The 1987 law requires a state license to engage in wholesale distribution in interstate commerce.

Miller pointed to bills being considered in Florida and California that would prohibit nonresident compounding pharmacies from shipping drugs into the state without a license or a permit. These measures could also affect firms registered with FDA as outsourcing facilities. The Florida bill specifies that outsourcing facilities must hold a state permit to distribute in the state.

Other states, Miller said, don't know what to do. "Both flags are on the flagpole" for outsourcing facilities, he said, using an analogy made by lawmakers.
"Until we get clarification, this is a gray area that will keep getting grayer," he said.

The intent of DQSA was to allow companies to choose to be regulated by the state or FDA, Alexander said, pressing FDA commissioner Margaret Hamburg for details about state laws applying to outsourcing facilities.
Hamburg told the Senate Health, Education, Labor and Pensions Committee that she had heard the opposite from states.
"What I've heard from states is that when there are these large facilities that are manufacturing high-risk injectable products, they often don't feel equipped to provide that regulatory oversight," she said. "They hope [these facilities] will register with the FDA."

DQSA, which was passed last year, created a new section, 503B of the Food, Drug and Cosmetic Act, in which large compounding pharmacies can voluntarily register with FDA and meet federal requirements for quality and inspections. Compounding facilities that do not to register must comply with manufacturing exemptions under section 503A, or be considered a drug manufacturer. The law was intended to clear up state and federal jurisdictional issues that were at issue during a deadly nationwide outbreak tied to drug compounding.

So far, 33 facilities are registered as outsourcing facilities, according to FDA records.

At the hearing, Hamburg also said that there are holes in the regulatory oversight of large compounding pharmacies. She said she is concerned that compounding pharmacies who aren't registered with the agency could be out of compliance with provisions of the law, but FDA may not know they even exist.

Hamburg also told the senator that the Good Manufacturing Practices (GMP) guidelines for outsourcing facilities under 503B is a top priority for the agency and they will be released as quickly as possible.
This discussion was part of a hearing held by the committee to examine FDA's initiatives in various areas, including developing abuse deterrent opioids, oversight of compounding facilities and food safety among other topics. -- Erin Durkin

IACP is continuing to monitor this situation, and will provide updates as they occur. Please email IACP at with any questions. 

FDA Tells Congress "No Office-Use" 

In addition to all the confusion surrounding Outsourcing Facilities (OFs), pharmacies have been told that office-use would continue to be governed under State laws. Specifically, there are more than six Statements on the Record from both the House and Senate stating that FDA does not have jurisdiction to prohibit pharmacies for compounding for office-use (or for the administration within a doctor’s office or hospital), and that it's an issue that should be left to the States.

FDA recently sent the House Energy & Commerce (E&C) Committee responses to Questions for the Record (QFRs) stating that despite the Congressional intent, FDA will use its “discretion” to prohibit all office-use compounding by pharmacies under 503A. FDA also has begun sending warning letters that express to pharmacies that solely based on the fact they are compounding for office-use for doctor’s office and/or hospitals, that they are a manufacturer and thus, in violation of the Food, Drug, and Cosmetic Act. This is represents a huge concern for pharmacies and Congress. To respond, it is IACP's understanding that Congressman Morgan Griffith (R-VA) intends to send a letter to FDA that expresses concern and disappointment with FDA’s most recent actions on prohibiting office use.

Click here for FDA’s most recent responses to the House E&C Committee regarding prohibiting office-use (the answer from FDA is on page 10)

IACP is continuing to monitor this situation, and will provide updates as they occur. Please email IACP at with any questions.

IACP March 25th Town Hall Recording Now Available


Thanks to the 91 member participants who joined our recent Town Hall call! If you missed IACP's Member Town Hall held on Tuesday, March 25th, the recording of the entire session is now available.

Topics Included: FDA Update; IACP’s API Bulk Drug List and FDA Pharmacy Compounding Advisory Committee Nominations; Progress on Constructive Transfer; New Marino Bill Update; and Compounders on Capitol Hill 2014 “Asks.”

Go to IACP's Members only Site, and click on Member Resources, then Town Hall Teleconference Recordings, and you will find the March 25th recording at the top of the Recording list.

Last Call for Nominations: IACP Task Force on Veterinary Compounding Legislation

Nominations will end today at 12 a.m., for the IACP Task Force on Veterinary Compounding Legislation. IACP is searching for individuals who are experts and knowledgeable in veterinary pharmacy compounding, and the needs of the veterinary practitioner. IACP's Task Force will develop a legislative proposal on veterinary compounding.
Nominations and resumes can be emailed to or faxed to 281/495-0602. We encourage you to forward this information to your colleagues who may be interested in participating on IACP's Task Force.

USP Proposed General Chapter <800> Hazardous Drugs - Handling in Healthcare Settings

The United States Pharmacopeia (USP) currently is seeking public review and comment on its proposed Chapter <800> Hazardous Drugs - Handling in Healthcare Settings. Click here to download this chapter with line numbers

All stakeholders are encouraged to submit comments with corresponding line numbers to Comments are due by July 31, 2014. Click here for more information. 

From the IACP AdvanCE Self-Paced Library: Don't Mess with Uncle Sam! How the Stark Law and the False Claims Act Impact Pharmacists

Glaxo Smith Kline -- $3 billion. Abbott -- $1.6 billion. J&J -- $2 billion. Those are the penalties just three drug companies have paid for violating the federal False Claims Act. Did you know that what got them into trouble was making claims about their drugs to prescribers for unapproved uses? But when many pharmacists hear the word “claims,” they believe the False Claims Act has to do with marketing. It doesn’t. It covers every single transaction between a provider of goods and services paid for by the federal government. That’s “claims” as in filing a claim for money. So, if you bill Medicaid or Medicare, the VA, or the Federal Employees Prescription Benefit Program, you are just as liable for violations of the False Claims Act as a major manufacturer. Unless you have a billion dollars or so just lying around, this is a must-attend webinar to protect yourself and your business from making costly mistakes.

Because any allegation of potential overbilling to a federal funded prescription or health benefit program – Medicaid, Medicare, TriCare, the Veterans Administration, the Federal Employees Health Plan – can be gravely serious, IACP offers members a self-paced webinar, Don’t Mess with Uncle Sam! How the Stark Law and the False Claims Act Impact Pharmacists. The Stark Law (also called the Anti-Kickback Law) and the False Claims Act impact every pharmacy that fills a prescription and bills a federally funded program and also any pharmacy who has a sales or marketing person generating compounded prescriptions which also result in a billing for physician services to those programs. To view this invaluable self-paced webinar, please click here. 

Click here for IACP's Press Release on its Stark Law and False Claims Act Webinar.  

Corporate Partner Spotlight: LicenseLogix

LicenseLogix helps pharmacies get licensed and stay licensed.

Targeted investigatory sweeps of unlicensed pharmacies are on the rise. State pharmacy boards have stepped up efforts to identify and shut down improperly licensed pharmacies. It is more important than ever for pharmacies of all types to stay educated and aware of the licensing requirements that may be pertinent to their operations.
LicenseLogix is a full service business licensing firm experienced in understanding the regulatory landscape for compounding pharmacies. Founded by a group of lawyers, technology professionals, and legal service industry veterans, LicenseLogix streamlines the process by which new and existing businesses obtain the proper licensing. LicenseLogix has helped many compounding pharmacies obtain and maintain licenses through our research, filing, and ongoing compliance services.

To be compliant, a compounding pharmacy generally must hold a valid pharmacy license in its designated home state and assign a licensed “pharmacist in charge” to each facility. The pharmacist in charge must maintain a valid license in the home state and is responsible for the pharmacy’s compliance with all applicable laws and rules. Furthermore, all staff pharmacists must hold valid licenses in the home state, or “domestic“ state, of the pharmacy.

In many states, compounding pharmacies need the same licenses as a regular retail pharmacy. A resident pharmacy license is required for in state pharmacies, while a non-resident or mail order pharmacy license is required for out of state pharmacies. Applications usually require sample labels, DEA Registration, inspection reports, and corporate documents. Compounding pharmacies must often provide supplemental information and attachments with each application. These can include internal policies and procedures of compounding practices, more stringent inspections, and proof of accreditation. Some states, such as California, Florida and Texas, have a separate license specifically for compounders.

If the pharmacy has additional locations or delivers drugs to patients in another state, the pharmacy must maintain a valid license in that state. Some states require that the pharmacist in charge hold an individual license in each additional state. Additionally, if the compounding pharmacy sells drugs wholesale, they may need to obtain a wholesale or drug distributor license in every state in which they transact business.

LicenseLogix offers personalized service with easy to use technology, ensuring that clients are properly licensed and that their questions are promptly answered. With LicenseLogix, each client has a dedicated account manager who helps determine the appropriate license(s) required, fills out any applications, and communicates with the relevant licensing authority. Your account manager will also walk you through our Client License Information Center (CLiC) and explain how to get the most out of this secure, web-based tool. All of your licenses and their renewal dates will be available to you in one centralized location – no more irritating spreadsheets, no more stacks of file folders, and, most importantly, NO MORE missed deadlines for license renewals.

LicenseLogix will help guide compounding pharmacies through the changing landscape of licensing requirements and regulations.  We can help you obtain all of the licenses and registrations you need, minimizing time-consuming and costly delays. To start the process now, click here or call us at (800) 292-0909.

Take Part in Insightful Continuing Education Sessions that Provide Tools and Resources to Advance Your Practice!

The 20th Annual Compounders on Capitol Hill (CCH) will be held May 17-20, 2014 at the Crystal Gateway Marriott in Arlington, Virginia. With an expected 400 total attendees in 2014, CCH brings together the top-level compounding pharmacists and technicians from across the country with the same goal – to protect pharmacy compounding. Don't miss the only pharmacy compounding event that takes our issues directly to Washington, D.C.'s doorstep.

Don’t miss these two engaging sessions on the Promoting Your Compounding Pharmacy Track on Monday, May 19, 2014.  

Monday, May 19, 2014
Engaging Patients as Advocates for the Compounding Pharmacy Profession
3:00-4:00 p.m.

This program is made possible through an unrestricted educational grant-in-aid from Analytical Research Laboratories (ARL).
Although everyone in the compounding community has focused upon the impact of the Drug Quality and Security Act, much, much more is occurring at both the state and federal level. Issues like constructive transfer of controlled substances, reimbursement for pharmacist care services, assured coverage of Active Pharmaceutical Ingredient (API)-based compounded medicines, and increasing scrutiny by regulators all mean that the battle to protect our specialty is as great as ever. Looking forward, IACP sees that our greatest advocates aren’t ourselves but our patients. This insightful seminar, conducted by IACP’s Washington D.C.-based advocacy experts, will show you how to capitalize on the passion and commitment of your patients, their families, and your local professional and business community.

At the conclusion of this educational session, the pharmacist and technician attendee will be able to:

  • Outline three essential steps in developing a comprehensive advocacy campaign.
  • Review two examples of how other businesses have executed successful advocacy campaigns.
  • Discuss how to leverage technology to achieve your goals.

Presented by:  Stephanie Mikos, Vice President, Business Development, DDC Advocacy

Program type:  Knowledge-Based

Back by popular demand, This Works for Me! returns to CCH and features a panel of IACP Members from across the country joining together to provide attendees with a variety of practice ideas to advance your practice.

Monday, May 19, 2014
This Works for Me!
4:00-5:30 p.m.

This program is made possible through an unrestricted educational grant-in-aid from the International Journal of Pharmaceutical Compounding (IJPC).
This is a session for IACP Members to share innovative practice ideas in the areas of hormone replacement supplements, topical pain therapies, vaginal delivery systems, quality measurements, patient seminars and marketing with new computer technologies.   This session will discuss programs they have developed within their pharmacy practice and the pharmacist and technician attendees may be able to implement in their pharmacy practice.

At the conclusion of this educational session, the pharmacist and technician attendee will be able to:

  • Identify innovative practice techniques not currently being utilized in attendees own pharmacy practice.
  • Discuss implementation of these techniques.
  • Discuss recent developments in pharmacy practice and how to take advantage of several new opportunities.

Presented by: Mark T. Burger, PharmD, Pharmacist/Owner, Health First! Pharmacy & Compounding Center; Jodi Burgess, PharmD, CDE, FACA, Potter's House Apothecary; Kate James, RPh, FIACP, Broadway Apothecary; Suzanne Keyes, PharmD, Keyes' Compounding & Specialty Drug; Rakesh Patel, RPh, MBA, WELLHealth Rx; Bev Smith, PharmD, Eric’s Pharmacy

Moderated by:  Robert Marshall, PharmD, Vital Care Pharmacy of Norfolk

Program type: Knowledge-Based

To review the meeting schedule, click here.  The 2014 Compounders on Capitol Hill printed brochure edition and e-brochure is sponsored by IACP Corporate Partner Freedom Pharmaceuticals, Inc. The Flipbook technology for the e-brochure was generously provided by RXinsider. To review the 2014 Compounders on Capitol Hill e-brochure, click here.

Reserve your hotel room online by
clicking here. The IACP hotel group discount ends Monday, April 21, 2014. To learn more about CCH, visit






20th Annual Compounders on Capitol Hill
May 17-20, 2014
Crystal Gateway Marriott
Arlington, Virginia  

Thank you to Our Exhibitors and Meeting Sponsors!

We would like to thank the following exhibitors for their commitment to Compounders on Capitol Hill: Accreditation Commission for Health Care (ACHC); AirClean Systems; American College of Apothecaries (ACA); Analytical Research Laboratories (ARL); Associates of Cape Cod, Inc.; ATS Labs; Attix Pharmaceuticals; B&B Pharmaceuticals, Inc.; Blesstia Pharmaceutical; Campbell University-Pharmaceutical Education and Research Center; Diversified Pharmaceutical Ingredients, LLC (DPI); DYNALABS; Eagle Analytical Services; EXAKT Technologies, Inc.; Fagron; Feras Health, LLC; Freedom Pharmaceuticals, Inc.; Frier Levitt LLC; Fuji Health Science, Inc.; Health Engineering Systems (HES); Humco Compounding; International Journal of Pharmaceutical Compounding (IJPC); International Medical Industries, Inc (IMI); KUNESA LLC; Letco Medical; Live Oak Bank; Medi-Dose, Inc./EPS, Inc.; MEDISCA; National Community Pharmacists Association (NCPA); Pharmacy Compounding Accreditation Board (PCAB); PCCA; Pure Encapsulations; RXinsider; RX TaxPros; RxCoop, LLC; Storey Marketing; Tacit Almonds, LLC; TeleManager Technologies; U.S. Pharmacopeial Convention (USP); Wellness Works; ZRT Laboratory.

We would like to thank the following meeting sponsors for their support of Compounders on Capitol Hill: American College of Apothecaries (ACA) (Continuing Education Provider); Analytical Research Laboratories (ARL) (Education Session); Attix Pharmaceuticals (First Timer Program); B&B Pharmaceuticals, Inc. (Meeting Tote Bag); Fagron (Meeting Syllabus); Freedom Pharmaceuticals, Inc. (Meeting Brochure/Commemorative Travel Mugs); Humco Compounding (Education Session/Door Drop Bag Insert); International Journal of Pharmaceutical Compounding (IJPC) (Education Session); International Medical Industries, Inc. (IMI) (Door Drop Bag Insert); Letco Medical (Welcome Reception Honoring IACP fellows/Education Session/CCH Lapel Pin); MEDISCA (Meeting T-shirt; Education Session); Microtest Laboratories, Inc. (Education Sessions (2)); PCCA (Hotel Room Keys/Name Badge Holder/Education Sessions (2)/Exhibitor and Monday Continental Breakfast & Lunch Sponsor); ProPharma Group (Door Drop Bag Insert); RX TaxPros (Education Session); Tacit Almonds, LLC (Relaxation Station); Torrey Hills Technologies, LLC (Education Sessions (2)); Topi-CLICK Topical Dosing Applicator (Conference Notepad/Pen Combo). 

We would like to thank the following individual and pharmacy meeting sponsors for their support of Compounders on Capitol Hill:  Presidential Sponsor: Darby Brown, RPh, PIC, Brown’s Compounding Center, Englewood, CO; Judicial Sponsor: Eddie Glover, PD, US Compounding, Conway, AR; John Herr, RPh, FIACP, Town & Country Compounding, Ridgewood, NJ; Rakesh Patel, RPh, WELLHealth Rx, Jacksonville, FL; Stan Reeves, PharmD, F & F Drugs, Demopolis, AL; Contributor Sponsors: Eyad Alsabbagh, Dr, Biomed Specialty Pharmacy, West Chester, OH; Mike Boehmer, RPh, Director, Compound Pharmaceutical Technologies, Daphne, AL;  Kevin Borg, President/CEO, PharmD, FIACP, FACA, Potter's House Apothecary, Peoria, AZ; Denise Burnham, RPh, Creative Compounds, Wilsonville, OR; Greg Chase, Pharmacist/Owner, Akina Pharmacy, Chantilly, VA; David Creecy, RPh, Poquoson Pharmacy, Poquoson, VA; Saad Dinno, RPh, FIACP, FACA, Acton Pharmacy, Acton, MA; Steve Hoyt, RPh, Owner, San Ysidro Pharmacy, Santa Barbara, CA; Brenda Jensen, CPhT, Compounding Consultants, LLC, Canton, SD; Richard Johnson, Pharmacist/Owner, Compounding Specialists of Wyoming, Casper, WY; Joe Lorello, RPh, Principal, Apothecary by Design, Portland, ME; Linda McElhiney, PharmD, RPh, FIACP, FACA, FASHP, Indiana University Health, Indianapolis, IN; Brenda Pavlic, CPhT, SaveWay Compounding, Newark, DE; Baylor Rice, RPh, FIACP, South Compounding River Pharmacy, Richmond, VA; Gener Tejero, RPh, Solutions Specialty Pharmacy, Las Vegas, NV; Tiffany Turner, Freedom Pharmaceuticals, Broken Arrow, OK; Doug Yoch, PharmD, Stanley Specialty Pharmacy, Charlotte, NC; Thomas Zieglar, RPh, Owner/PIC, Medicap Pharmacy, Ashburn, VA.

To learn more about the exhibitors and meeting sponsors, click here. 

IACP Welcomes New Corporate Partner: Polsinelli PC

The IACP Corporate Partner program engages corporate leaders in the pharmacy compounding community by connecting them with more than 3,600 IACP affiliates who are focused upon the specialty practice of pharmacy compounding. We encourage all IACP members to support these corporate partners who are instrumental in our joint effort to protect and grow this vital part of quality healthcare.

Join Polsinelli's Live Webinar on Tuesday, April 8, 2014, New Compounding Pharmacy Law: Compliance Issues for Business and Risk Analysis for Investors. Click here for more information!

To learn more about Polsinelli PC, please visit

IACP Regional Education Meeting Heading to Newark, NJ; Atlanta, GA; and Dallas, TX


The IACP Regional Education Meeting brings 2.0 contact hours (.20 CEUs) of live pharmacy law continuing education credit to pharmacists and technicians all across the United States. Listen to David G. Miller, RPh, IACP’s Executive Vice President & CEO as he presents, Pharmacy Compounding Law and Regulations: Staying Current in a Changing World, an in-depth presentation on federal and state legislative and regulatory issues that are affecting compounders today.

Attendees will learn how regulatory initiatives and court decisions have influenced the regulation of compounders, the authority of the Food and Drug Administration (FDA) when inspecting compounding pharmacies, and up-to-date information on the current federal proposed legislation. Are YOU current on your compounding pharmacy law? Never assume.

We hope you’ll join us for an evening of compounding pharmacy law education, Q&A, and networking with your local compounders! For more information, please visit

Newark, New Jersey – June 18, 2014
7:00 - 9:30 p.m.
NJIT Enterprise Development Center, #407 (EDC Conference Center)
211 Warren Street, Newark, New Jersey 07103

IACP Members: $50; Non-Members: $75; Student Pharmacists: FREE

Thank you to TeleManager Technologies for hosting this meeting.

Atlanta, Georgia – September 9, 2014
7:00 - 9:30 p.m.
Mercer University’s College of Pharmacy
3001 Mercer University Drive, Atlanta, GA 30341

FREE! This seminar is open to pharmacists, technicians, marketing representatives, and pharmacy students at no cost thanks to Topi-CLICK Topical Dosing Applicator and Mercer University’s College of Pharmacy.

This program was made possible through an unrestricted educational grant-in-aid from Topi-CLICK Topical Dosing Applicator.

Thank you to Mercer University’s College of Pharmacy for hosting this meeting.

Dallas, Texas – September 20, 2014
Omni Hotel in Dallas

IACP Members: $50; Non-Members: $75; Student Pharmacists: FREE

This meeting will correspond with the Freedom Pharmaceuticals, Inc. 3rd Annual Seminar, September 18-20.

Would You Like to Sponsor or Host an IACP Regional Education Meeting in Your City?
If you would like IACP to plan a Regional Education Meeting in your city, please email Michelle Greene Atkinson or call 281.933.8400. For more information on sponsorship, please click here. For more information on hosting, please click here.   

IACP Calendar

IACP is your one-stop resource for all things compounding! CompounderCalendar provides a comprehensive listing of compounding events and continuing education programs. Click here to view IACP’s Upcoming Events.

IACP Career Center

Welcome to the IACP Career Center! Your destination for exciting job opportunities and the best resource for qualified candidates within the Industry. Click here to view the IACP Career Center.

Stay connected to IACP by joining our online communities!



Association Management Software Powered by YourMembership  ::  Legal